Database

Startups

Main Industry
Health Care
Main Product/Service
1. Development of botanical new drug
2. Certificated TAF testing service
Founded Year
2016
Unified Business No.
42861402
Status
Active
Number of Employees
16
Total Paid-in Capital
232,300,000 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Introduction
BELX Biopharmaceuticals is an R&D oriented biotech company,focusing on developing botanical new drugs to treat tumors, infectious diseases, and aging-related chronicle diseases.



More ↓
Corporate Video

Similar Companies

TAIRX, INC.

1. CVM-1118 (Foslinanib)
2. ZelniteR
3. TRX-NOC
4. TRX-920
5. TRX-105

XANTHO BIOTECHNOLOGY CO., LTD.

*Botanical New Drug*
The main therapeutic area we are focusing on is dermatology. With the aim of improving the quality of life for patients, we develop products with market profitability and improved clinical effectiveness for patients in different age groups, thereby contributing to the well-being of human.
*Immunity and Inflammation*
The botanical new drug GM-XANTHO, a topical drug developed by Xantho Bio., is now in phase 2 study for atopic dermatitis (AD). GM-XANTHO is shown to be safe and well-tolerated in human, and it is expected to be more accessible to AD patients compared to injectables and oral drugs. It is anticipated that the results of the Phase IIa clinical study will be available in Q2 2025.